



ASX & Media Release

## Patrys Granted Australian Patent for Late Stage Preclinical Product PAT-LM1

- PAT-LM1 patent granted in Australia that offers protection through to June 2029
- Broadly, the patent covers the PAT-LM1 antibody for use in treating metastasis

**Melbourne, Australia; 30 September, 2014:** Patrys Limited (**ASX: PAB**), a clinical stage biotechnology company is pleased to advise that it has been granted the first Australian patent for anti-cancer product PAT-LM1.

The Australian Patent Office has issued correspondence confirming the grant of a key patent in the PAT-LM1 family; patent number 2009269704; entitled "LM-antibodies, functional fragments, LM-1 target antigen, and methods for making and using same".

The Australian patent is derived from one of a series of patent applications that have been submitted to cover the PAT-LM1 product, target and epitope. The claims in this patent cover the use of PAT-LM1 or binding fragments of PAT-LM1 for the treatment of metastasis in various cancers including brain, breast, stomach and liver as examples.

To date, four patents across the PAT-LM1 families have been granted in three jurisdictions including the United States, New Zealand and Australia.

"This new patent strengthens and enhances the current intellectual property position for PAT-LM1. We look forward to updating the market on the development with this program", said Dr. Marie Roskrow, Patrys' Chief Executive Officer.

In September 2014, Patrys announced it had completed the process development for PAT-LM1 and is moving into the scale-up portion of the development/manufacturing plan. Patrys continues to explore the best clinical indication for this antibody, especially those with a significant unmet medical need, orphan indications and niche markets.

Patrys has additional applications pending across the PAT-LM1 families in Europe, Canada, Japan and the United States.

**-Ends-**

**For further information, please contact:**

*Patrys Limited:*  
Dr. Marie Roskrow  
Chief Executive Officer  
P: +61 3 9670 3273  
[info@patrys.com](mailto:info@patrys.com)

*Patrys IR:*  
Kyahn Williamson  
Buchan Consulting  
P: +61 3 9866 4722  
[kwilliamson@buchanwe.com.au](mailto:kwilliamson@buchanwe.com.au)

*Patrys Media:*  
Kellie Hanrick  
Buchan Consulting  
P: +61 3 9866 4722  
[khanrick@buchanwe.com.au](mailto:khanrick@buchanwe.com.au)

**About Patrys Limited:**

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of natural human antibodies as therapies for cancer and other major diseases. Patrys has a deep pipeline of anti-cancer natural human antibodies that enable both internal development and partnering opportunities. More information can be found at [www.patrys.com](http://www.patrys.com)

**About PAT-LM1:**

PAT-LM1 is a natural human IgM antibody that binds to a proprietary disease target NONO that is expressed on the surface of cancer cells, but not on the surface of the healthy tissues. Binding of PAT-LM1 to NONO causes cell death through interference with the gene regulation mechanisms inside the cells. PAT-LM1 has been shown to have potent anti-cancer properties in a large number of laboratory and animal studies. With over 200 individual patient tumours screened, covering several different cancers, PAT-LM1 binds to nearly 98% of those tumours regardless of cancer type, age, gender or disease stage. PAT-LM1 is now moving towards the scale-up manufacturing process in preparation for a future clinical trial. The clinical indication for PAT-LM1 is yet to be determined. Patrys has patents granted that cover the PAT-LM1 molecule and its method of treatment.